Analysts predict that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) will post $21.92 million in sales for the current quarter, Zacks reports. Five analysts have made estimates for Deciphera Pharmaceuticals’ earnings. The highest sales estimate is $26.30 million and the lowest is $18.50 million. Deciphera Pharmaceuticals posted sales of $60,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 36,433.3%. The company is scheduled to issue its next earnings results on Tuesday, May 4th.
On average, analysts expect that Deciphera Pharmaceuticals will report full-year sales of $119.12 million for the current year, with estimates ranging from $91.49 million to $160.00 million. For the next financial year, analysts expect that the company will post sales of $255.81 million, with estimates ranging from $203.50 million to $317.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Deciphera Pharmaceuticals.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Monday, February 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.06. The firm had revenue of $19.49 million during the quarter, compared to analysts’ expectations of $18.68 million.
Shares of NASDAQ DCPH traded up $0.10 during trading hours on Wednesday, reaching $46.00. The stock had a trading volume of 412,560 shares, compared to its average volume of 438,570. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -9.20 and a beta of 1.49. The business’s fifty day moving average price is $44.15 and its two-hundred day moving average price is $52.39. Deciphera Pharmaceuticals has a 52-week low of $39.42 and a 52-week high of $68.40.
In related news, Director Michael Douglas Taylor sold 8,000 shares of the company’s stock in a transaction on Thursday, April 1st. The stock was sold at an average price of $45.57, for a total value of $364,560.00. Following the transaction, the director now directly owns 8,000 shares of the company’s stock, valued at approximately $364,560. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director James Arthur Bristol sold 5,300 shares of the company’s stock in a transaction on Monday, April 19th. The shares were sold at an average price of $46.26, for a total value of $245,178.00. Following the completion of the transaction, the director now directly owns 5,300 shares in the company, valued at $245,178. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,000 shares of company stock worth $1,254,186. Insiders own 7.02% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in shares of Deciphera Pharmaceuticals by 4.6% in the 4th quarter. BlackRock Inc. now owns 3,409,858 shares of the company’s stock valued at $194,599,000 after acquiring an additional 150,286 shares during the period. Wells Fargo & Company MN grew its position in Deciphera Pharmaceuticals by 35.8% during the 4th quarter. Wells Fargo & Company MN now owns 702,387 shares of the company’s stock worth $40,085,000 after purchasing an additional 185,093 shares during the period. Deerfield Management Company L.P. Series C grew its position in Deciphera Pharmaceuticals by 25.4% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 528,585 shares of the company’s stock worth $27,116,000 after purchasing an additional 106,906 shares during the period. Norges Bank acquired a new stake in Deciphera Pharmaceuticals during the 4th quarter worth about $24,762,000. Finally, Hood River Capital Management LLC grew its position in Deciphera Pharmaceuticals by 69.3% during the 4th quarter. Hood River Capital Management LLC now owns 425,661 shares of the company’s stock worth $24,292,000 after purchasing an additional 174,280 shares during the period. 73.61% of the stock is currently owned by hedge funds and other institutional investors.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors.
Recommended Story: How Do Front-End Loads Impact an Investment?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.